WO2012078525A3 - Compositions and methods for treating ophthalmic conditions - Google Patents

Compositions and methods for treating ophthalmic conditions Download PDF

Info

Publication number
WO2012078525A3
WO2012078525A3 PCT/US2011/063338 US2011063338W WO2012078525A3 WO 2012078525 A3 WO2012078525 A3 WO 2012078525A3 US 2011063338 W US2011063338 W US 2011063338W WO 2012078525 A3 WO2012078525 A3 WO 2012078525A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
ophthalmic conditions
treating ophthalmic
rbp
Prior art date
Application number
PCT/US2011/063338
Other languages
French (fr)
Other versions
WO2012078525A2 (en
Inventor
Mark Edgar
Jay Lichter
Nathan L. Mata
Original Assignee
Revision Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revision Therapeutics, Inc. filed Critical Revision Therapeutics, Inc.
Priority to EP11847841.1A priority Critical patent/EP2648711A2/en
Publication of WO2012078525A2 publication Critical patent/WO2012078525A2/en
Publication of WO2012078525A3 publication Critical patent/WO2012078525A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

Compositions of novel fenretinide powders that reduce serum RBP, and/or serum retinol- RBP levels are used to treat ophthalmic conditions such as geographic atrophy (GA), an advanced form of dry AMD and the prevention of choroidal neovascularization (CNV, or wet AMD).
PCT/US2011/063338 2010-12-06 2011-12-05 Compositions and methods for treating ophthalmic conditions WO2012078525A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11847841.1A EP2648711A2 (en) 2010-12-06 2011-12-05 Compositions and methods for treating ophthalmic conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42021110P 2010-12-06 2010-12-06
US61/420,211 2010-12-06

Publications (2)

Publication Number Publication Date
WO2012078525A2 WO2012078525A2 (en) 2012-06-14
WO2012078525A3 true WO2012078525A3 (en) 2012-09-27

Family

ID=46207669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/063338 WO2012078525A2 (en) 2010-12-06 2011-12-05 Compositions and methods for treating ophthalmic conditions

Country Status (2)

Country Link
EP (1) EP2648711A2 (en)
WO (1) WO2012078525A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
AU2015292212B2 (en) 2014-07-25 2019-03-14 Laurent Pharmaceuticals Solid oral formulation of fenretinide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015827A1 (en) * 2005-07-11 2007-01-18 Sytera, Inc. Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
US20080176952A1 (en) * 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US20090088435A1 (en) * 2007-09-27 2009-04-02 Sirion Therapeutics, Inc. Methods and compounds for treating retinol-related diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080176952A1 (en) * 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US20070015827A1 (en) * 2005-07-11 2007-01-18 Sytera, Inc. Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
US20090088435A1 (en) * 2007-09-27 2009-04-02 Sirion Therapeutics, Inc. Methods and compounds for treating retinol-related diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D. GIRON: "Investigations of polymorphism and pseudo-polymorphism in pharmace uticals by combined thermoanalytical techniques.", JOURNAL OF TERMAL ANALYSIS AND CALORIMETRY., vol. 64, no. 1, 1 April 2001 (2001-04-01), pages 37 - 60, XP009035635 *

Also Published As

Publication number Publication date
EP2648711A2 (en) 2013-10-16
WO2012078525A2 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
EP3911371A4 (en) Methods and compositions to improve the safety and efficacy of cellular therapies
AU2015279424A8 (en) Difluoromethyl-nicotinic-indanyl carboxamides
MY161495A (en) Virus like particle compositions and methods of use
MY163031A (en) Method of treating obesity using antioxidant inflammation modulators
WO2013040033A8 (en) Methods and compositions for weed control
WO2012083048A3 (en) Anti-viral compounds
WO2012083053A3 (en) Anti-viral compounds
WO2013177419A3 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
AU2016219704A1 (en) Anti-Notch1 antibodies
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
EA201790446A1 (en) CYTOTOXIC BENZODIAZEPINE DERIVATIVES
WO2012083061A3 (en) Anti-viral compounds
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
MX2012005782A (en) Lyophilization methods, compositions, and kits.
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
WO2015161243A3 (en) Beta-lactamases with improved properties for therapy
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2012083058A3 (en) Anti-viral compounds
WO2012057575A3 (en) Feed additive composition containing turmeric extracts and stevia extracts as active ingredients for increasing resistance to white spot syndrome viruses, and feed composition comprising same
PH12017500615B1 (en) Ophthalmic composition comprising cyclosporine and trehalose
WO2012056478A8 (en) Oxazoline and isoxazoline derivatives as crac modulators
WO2013164839A8 (en) Amorphous form of apixaban, process of preparation and compositions thereof
WO2012162580A3 (en) Anti-viral compounds
WO2013123249A3 (en) Formulations and methods for treating ear conditions
WO2011160060A3 (en) Selenium attachment agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11847841

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013543237

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011847841

Country of ref document: EP